Comprehensive Online Oncology Database	REPORT FORMAT New Drug Target Table Note: Report links have been disabled for this sample screen.	SUBSCRIBER SEARCH (Requires Login) NEW DRUG MARKETED DRUG COMPANY TARGETS IN ONCOLOGY NEWS AND WEBCAST SUMMARIES COMBINATION TRIALS
1-949-830-0448		info@newmedinc.com

Your search found 15 records. Click on a developer link to see more information.

Developer	Designation	Target	Development Status & Location - Indications
Allos Therapeutics Affiliate(s): · Cancer Research Technology · University of Colorado · University of Salford Current as of: December 04, 2007	Other Designation: RH1, RH-1 Description: RH1, a novel diaziridinylbenzoquinone, is a targeted cytotoxic prodrug bioactivated by the enzyme DT-diaphorase (DTD), which is overexpressed in many tumors relative to normal tissue.	DT-diaphorase (DTD), NAD(P)H dehydrogenase, quinone 1 (NQO1)	Phase I (begin 9/03, completed 6/06) Europe (UK); phase I (begin 11/07) USA - solid tumors, advanced, refractory • non-Hodgkin's lymphoma (NHL), advanced, refractory or relapsed Phase I (begin 11/07) USA - solid tumors, advanced, refractory • non-Hodgkin's lymphoma (NHL), advanced, refractory
Mitsubishi Pharma Affiliate(s): · Aveo Pharmaceuticals Current as of: December 01, 2007	Other Designation: MP-412 • AV-412 Description: MP-412 is a novel compound of the anilinoquinazoline class that inhibits both epidermal growth factor receptor (EGFr), and HEr2/neu tyrosine kinases.	Epidermal growth factor (EGF) receptor (EGFr, ErbB-1, ErbB1, HEr-1, HEr1) • HEr2/neu (HEr-2/neu, ErbB-2, c-erbB-2, ErbB2)	Phase I (begin 10/06, ongoing 7/07) USA, Argentina, phase I (begin 10/07) USA - solid tumors, advanced, rfractory or relapsed
Schering-Plough Affiliate(s): · Xoma · Aveo Pharmaceuticals Current as of: December 01, 2007	Other Designation: AV-299 Description: AV-299 is a novel, potent, anti-hepatocyte growth factor/scatter factor (HGF/SF) monoclonal antibody (MAb).	Hepatocyte growth factor/scatter factor (HGF/SF or SF/HGF)	Preclin (ongoing 12/07) USA - solid tumors
Wyeth Current as of: December 01, 2007	Other Designation: HKI-272 Description: HKI-272 is an orally active, irreversible inhibitor of the HEr2 tyrosine kinase that also inhibits the epidermal growth factor receptor (EGFr) kinase and proliferation of EGFr-dependent cells.	HEr2/neu (HEr-2/neu, ErbB-2, c-erbB-2, ErbB2) • Epidermal growth factor (EGF) receptor (EGFr, ErbB-1, ErbB1, HEr-1, HEr1)	Phase I (begin 11/03, closed 12/05) USA - solid tumors, Her2/neu-positive Phase II (begin 3/06, ongoing 7/07) USA, Europe (Belgium, Netherlands, Russia), India, Brazil - breast cancer, advanced (Stage IIIb/c) or metastatic, overexpressing ErbB2 Phase II (begin 11/05, closed 9/07) USA, Europe (France, Hungary, Poland, Spain) - non-small cell lung cancer (nsclc), advanced
Syndax Pharmaceuticals Affiliate(s): · Bayer Schering Pharma Current as of: December 01, 2007	Other Designation: MS-275 • MS275 • SNDX-275 Description: MS-275, a benzamide derivative, is a HDAC1 and HDAC3 inhibitor with potent and unique cytotoxicity and anticancer activity.	Histone deacetylase (HDAC)	Phase I (began 3/01, closed 06) USA; phase I (begin 11/04, closed 9/06) USA (combination) - solid tumors, refractory • non-Hodgkin's lymphoma (NHL), refractory Phase I (begin 2/01, closed 7/05) USA - leukemia, advanced, refractory • hematologic malignancies Phase I (begin 12/04, closed 8/07) USA (combination) - chronic myelomonocytic leukemia (CML) • myelodysplastic syndrome (MDS) • acute myeloid leukemia (AML) Phase II (begin 12/04, completed 11/06) USA - melanoma, malignant, advanced Phase I/II (begin 8/06, ongoing 12/07) USA - non-small cell lung cancer (nsclc), metastatic or inoperable, refractory, second line
Roche Affiliate(s): · Genmab Current as of: December 04, 2007	Other Designation: R1507 Description: R1507 is fully human monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-1r).	Insulin-like growth factor 1 receptor (IGF1r, IGF-1r, IGFIr, IGF-Ir)	Phase I (begin 4/06, closed 9/07) USA - solid tumors, locally advanced or metastatic • non-Hodgkin's lymphoma (NHL), advanced • Hodgkin's lymphoma, advanced
ArQule Affiliate(s): · Kyowa Hakko Kogyo Current as of: December 03, 2007	Other Designation: ARQ-650RP • ARQ 650RP • ARQ 197 • ARQ197 Description: ARQ 197 an orally administered, proprietary small molecule c-Met inhibitor is the lead compound of a series of proprietary compounds generated through ArQule’s Cancer Survival Protein (CSP) modulation program.	Met [hepatocyte growth factor receptor (HGFr)/c-Met]	Phase I (begin 2/06, closed 1/07, completed 6/07) USA - solid tumors, metastatic, refractory - pancreatic cancer, inoperable, locally advanced or metastatic, first line Phase II (begin 10/07) USA - microphthalmia transcription factor associated (MiT) tumors, inoperable locally advanced or metastatic
SGX Pharmaceuticals Current as of: December 04, 2007	Other Designation: SGX-523 Description: SGX-523 is an inhibitor of Met receptor tyrosine kinase implicated in a broad range of solid tumors.	Met [hepatocyte growth factor receptor (HGFr)/c-Met]	IND (filed 12/07) USA - solid tumors
VistaGen Therapeutics Current as of: December 04, 2007	Other Designation: AV-101 • 4-Cl-KYN Description: AV-101, a potential 'first-in-class' prodrug that regulates glutamate signaling by regulating the NMDA receptor, may reduce the severity of neuropathic pain.	N-methyl-D-aspartate (NMDA)	Preclin (ongoing 12/07) USA - pain, chronic, neuropathic
Peregrine Pharmaceuticals Affiliate(s): · University of Texas Southwestern Medical Center Current as of: December 04, 2007	Generic Name: Bavituximab Brand Name: Tarvacin Other Designation: 3G4 Description: Bavituximab is a chimeric version of 3G4, a monoclonal antibody (MAb) that binds to the phospholipid phosphatidylserine (PS) on the surface of tumor endothelial cells.	Phosphatidyserine (PS)	Phase I (begin 6/05, completed 7/07) USA; phase Ib (begin 9/06, completed 3/07) India - solid tumors, advanced Phase II (planned 7/07) India (combination) - non-small cell lung cancer (nsclc) Phase II (planned 9/07) India (combination); phase II (begin 11/07) Republic of Georgia (combination) - breast cancer, advanced or metastatic
AEterna Zentaris Affiliate(s): · Keryx Biopharmaceuticals Current as of: December 04, 2007	Generic Name: Perifosine Other Designation: KRX-0401, D-21266 Description: Perifosine, a novel heterocyclic alkylphospholipid (alkylphosphocholine derivative) analog of hexadecylphosphocholine (miltefosine), is an oral Akt inhibitor that activates the MAP kinase (MEK/ERK) pathway leading to the activation of p21 independently of p53.	Protein kinase C (PKC) • Akt (protein kinase B, PKB)	Phase I (begin 7/96, ongoing 5/99) Europe (Germany), phase I (begin 2/99, completed 5/04) USA, phase I (begin 2/00, completed 12/03) USA, phase I (completed 6/04) Europe (Netherlands) (combination), phase I (begin 11/04, closed 12/06) USA (combination), phase I (begin 8/04, ongoing 1/06) USA (combination), phase I (begin 10/06, ongoing 11/07) USA; phase IIa (begin 1/05, ongoing 11/07) USA - solid tumors, advanced, refractory Phase II (begin 7/03, completed 9/05) USA, phase II (begin 8/03, suspended 4/04) Canada - pancreatic cancer, locally advanced or metastatic • adenocarcinoma, advanced, pancreatic Phase II (begin 3/03, closed 6/05) USA, phase II (begin 4/03, completed 3/05) USA - prostate cancer, hormone-sensitive, biochemically recurrent • prostate cancer, metastatic, androgen-independent Phase II (begin 6/03, closed 6/05) Canada, phase II (begin 5/05, ongoing 1/06) USA (combination) - breast cancer, locally advanced or metastatic, recurrent or refractory, Er or Pr positive Phase II (begin 6/03, closed 3/04) USA, phase II (begin 6/03, suspended 4/04) Canada; phase II (begin 12/06, ongoing 11/07) - sarcoma, soft tissue, locally advanced or metastatic Phase II (begin 6/03, completed 12/05) Canada - melanoma, metastatic or recurrent, first line Phase II (begin 5/03, completed 7/04) USA - head and neck cancer, metastatic or recurrent Phase I/II (begin 9/04, ongoing 11/07) USA; phase II (begin 9/05, closed 11/07) (multimodality) Europe (Netherlands) - non-small cell lung cancer (nsclc), refractory Phase I/II (begin 8/06, ongoing 12/06) USA (combination); phase II (begin 1/06, closed 10/07) USA (combination); phase I (begin 12/06, ongoing 2/07) USA (combination) - multiple myeloma, relapsed or refractory Phase I (begin 3/06, ongoing 2/07) USA (combination) - chronic myelogenous leukemia (CML) Phase II (begin 10/06, ongoing 11/07) USA - glioma, malignant, recurrent or progressive • glioblastoma multiforme, recurrent, malignant Phase II (begin 8/05, ongoing 11/07) USA - solid tumors, metastatic Phase I (begin 10/06, ongoing 11/07) USA (combination), phase I (begin 10/06, ongoing 11/07) USA (combination); phase II (begin 3/07, ongoing 11/07) USA; phase II (begin 7/07, ongoing 11/07) USA - renal cell carcinoma (RCC), advanced • gastrointestinal stromal tumors (GIST), advanced • hepatocellular carcinoma (HCC), advanced
Idera Pharmaceuticals Affiliate(s): · Aegera Therapeutics · Isis Pharmaceuticals Current as of: December 04, 2007	Brand Name: IMOxine Other Designation: HYB2055 • IMO-2055 Description: IMOxine is a second generation immunomodulating oligonucleotide (IMO) agonist of Toll-like receptor 9 (TLr9) containing a CpR dinucleotide motif.	Toll-like receptor 9 (TLr9), CD289	Phase I (begin 5/03, ongoing 3/05) USA, phase I (completed 5/03) Europe (UK); phase I/II (begin 10/06) USA (combination) - solid tumors, advanced, refractory Phase II (begin 10/04, ongoing 10/06) USA - renal cell carcinoma, metastatic or recurrent
Nerviano Medical Sciences Current as of: December 01, 2007	Generic Name: Nemorubicin HCl Other Designation: PNU-152243 • FCE-23762 Description: Nemorubicin or methoxymorpholinyl doxorubicin (MMDX) is a morpholinyl analog and lipophilic doxorubicin derivative that inhibits topoisomerase I and II but predominantly topoisomerase I.	Topoisomerase II • Topoisomerase I	Phase I/II (completed /00) Europe (The Netherlands) - ovarian cancer Phase II/III (ongoing 2/05) China; phase I/II (closed 06/06) Europe, China - hepatocellular carcinoma (HCC), inoperable Phase II (begin 11/95, closed 11/96) - sarcoma, advanced Phase I (completed /99) Switzerland; (completed 8/97) USA • Phase II (completed /98) The Netherlands - solid tumors
Aveo Pharmaceuticals Current as of: December 03, 2007	Other Designation: AV-951 Description: AV-951 is a novel, highly potent and specific inhibitor of vascular endothelial growth factor receptors VEGFr1, VEGFr2, and VEGFr3.	Vascular endothelial growth factor (VEGF) receptor 1 (VEGFr1, Flt-1) • Vascular endothelial growth factor (VEGF) receptor 2 (VEGFr2, VEGFr-2) / (FLK1, Flk-1) / KDR • Vascular endothelial growth factor (VEGF) receptor 3 (VEGFr3, VEGFr-3) / (FLT4, Flt-4) / PCL	Phase I (closed 07) USA - solid tumor, advanced Phase II (begin 10/07) Europe (Russia), India; phase I (closed 11/07) USA (combination) - renal cell carcinoma (RCC), advanced • renal cell carcinoma (RCC), recurrent or metastatic, second line
Exelixis Affiliate(s): · GlaxoSmithKline Current as of: December 04, 2007	Other Designation: XL184 • EXEL-7184 Description: XL184 is a small molecule potent inhibitor of the hepatocyte growth factor receptor (Met) and VEGFr2 (KDr) tyrosine kinases (RTK), preventing tumor growth, and inducing regression of various types of large tumors in xenograft models.	Vascular endothelial growth factor (VEGF) receptor 2 (VEGFr2, VEGFr-2) / (FLK1, Flk-1) / KDR • Met [hepatocyte growth factor receptor (HGFr)/c-Met]	Phase I (begin 9/05, ongoing 11/07) USA - solid tumors, advanced, refractory • lymphoma, advanced, refractory

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM